Incyte (INCY) Misses Q4 EPS by 76c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
February 8, 2022 7:00 AM ESTTotal product and royalty revenues of $813 million (+20%) in Q421 and $2.891 billion (+17%) in FY21 Jakafi® (ruxolitinib) net product revenues of $592 million (+15%) in Q421 and $2.135 billion (+10%) in FY21; Jakafi guidance range of $2.3 to $2.4 billion for 2022 Successful U.S. launch of Opzelura (ruxolitinib) cream in atopic dermatitis with nearly 19,000 patients treated from launch (October 11th) through the end of the year Vitiligo is the next substantial growth opportunity for ruxolitinib cream under Priority Review in the U.S. and under review in Europe
Conference Call and Webcast Scheduled Today at 8:00 a.m.... More
